International Partnering in Lifescience Society (IPLS)

With March drawing to its end, make sure to not miss the application deadline of April 17th, 2025, for the Swiss HLG Start-Up Initiative in collaboration with Johnson & Johnson and BaseLaunch. Seize the opportunity and get fit for partnering!

The Swiss HLG & Pharmaceutical Licensing Group cordially invite you to join us for this timely webinar: 27th March from 13.30-15.30 UK/ 14:30 -16:00 CET/8:30 - 10:00 EST USA & China - how the environment is changing & how this could impact deal-making. Fast changing times call for agile deal making strategies. Join us for strategic insights on the future evolution of the US and China pharmaceutical markets and how this could impact deal making. Howard Chen, Managing Principal and Head of Services at IQVIA China, brings a wealth of experience in management consulting and investment banking, particularly in the healthcare sector. He has been with IQVIA since 2017 and has over 17 years of experience in the industry, including cross-border M&A deals and fundraising for various healthcare players. Hisinsights on the China perspective are highly valued in the industry. Michael Margolis, Senior Managing Director and Head of Healthcare Investment Banking at Oppenheimer & Co., is known for his expertise in healthcare investment banking. He has advised numerous organizations on strategic growth initiatives and has a deep understanding of the US healthcare market. His perspective on the US healthcare landscape is highly regarded. Would you like to know more about their specific viewpoints Please sign up to this Live Webinar. Free of Charge These two live sessions will be followed by a Q&A Register Here: https://lnkd.in/eGczBRBQ

Agenda Update. We are thrilled that Dr. Johanna Ludwig has agreed to be our keynote speaker in Berlin. We have also secured the Berliner Fernsehturm Sphere Restaurant for the gala dinner. More updates to follow Do not forget our super early bird discount expires Friday 28th. Register here: https://lnkd.in/e3bb6AR All Welcome

Listen to Michelle Chen share why she finds it so worthwhile to attend the Swiss HLG Annual Conference. Join us from 25th - 27th May 2025, in beautiful Montreux, you will have the opportunity to learn, celebrate, establish and foster new relationships that expand your business network in this wonderful setting. The theme of our conference is ¨“Shaping your future..... Act now!” - focused on creative dealmaking to optimize portfolio strategy in a fast-changing environment. 📌𝗪𝗲 𝗵𝗮𝘃𝗲 𝗮𝗻 𝗘𝗮𝗿𝗹𝘆 𝗕𝗶𝗿𝗱 𝘀𝗽𝗲𝗰𝗶𝗮𝗹 𝘆𝗼𝘂 𝗰𝗮𝗻 𝗯𝗲𝗻𝗲𝗳𝗶𝘁 𝗳𝗿𝗼𝗺 - 𝗶𝗳 𝘆𝗼𝘂 𝗿𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗯𝗲𝗳𝗼𝗿𝗲 𝗙𝗲𝗯𝗿𝘂𝗮𝗿𝘆 𝟮𝟴𝘁𝗵, 𝟮𝟬𝟮𝟱 𝘁𝗵𝗲𝗻 𝘆𝗼𝘂 𝘄𝗶𝗹𝗹 𝗼𝗯𝘁𝗮𝗶𝗻 𝗮 𝟱𝟬% 𝗱𝗶𝘀𝗰𝗼𝘂𝗻𝘁 𝗼𝗻 𝘆𝗼𝘂𝗿 𝟮𝟬𝟮𝟱 𝗦𝘄𝗶𝘀𝘀 𝗛𝗟𝗚 𝗺𝗲𝗺𝗯𝗲𝗿𝘀𝗵𝗶𝗽 𝗳𝗲𝗲.📌 👉Register here ➡https://lnkd.in/eufMZpng #swisshlg #biopharma #dealmaking #innovation #networking #SwissHLGconference #conference2025

Our Super Early Bird Discount ends soon in just two weeks. Register here: https://lnkd.in/e3bb6AR

Meet our esteemed Key Note speaker from Teva Pharmaceuticals at the upcoming Swiss HLG conference in beautiful Montreux on May 25-27. Konstantina Katcheves is SVP, Global Business Development for Innovative Medicines. A seasoned dealmaker and enterprise leader, Konstantina has more than 20 years of life sciences and pharmaceuticals experience with demonstrated success in international leadership, business strategy, intellectual property, and negotiation of international partnerships. At Teva, Konstantina is building and developing an innovative medicines business development team and strategy to help drive Teva’s Pivot to Growth. Her team focuses on partnerships in neuroscience, immunology and rare disease leveraging Teva’s development capabilities and commercial strength across the globe to deliver more innovative medicines. Prior to joining Teva, Konstantina was SVP for business development at Bristol Myers Squibb (BMS) and also interim head of Enterprise Strategy & BD leading BMS through a historic quarter of major and transformative transactions. Prior to that, she led BMS in collaborations at various stages across therapeutic areas, including early discovery partnerships, digital innovation, precision medicine and cell and gene therapy technologies, and regional business development for Japan and China. As a leader in life sciences, Konstantina has a personal and professional interest in supporting women’s health initiatives and women’s success as a mentor to other females in science and healthcare Konstantina has held leadership positions as both a lawyer and a BD leader, including VP of Intellectual Property & Licensing at Agilent Technologies and VP of Global Intellectual Property, Licensing and Strategic Alliance at Lonza. Konstantina holds a Bachelor of Science in cell biology and biochemistry from the University of California at San Diego, a Juris Doctor from the University of Oklahoma College of Law, and a Master of Science in Biotechnology from Johns Hopkins University. The theme of our conference is ¨“Shaping your future..... Act now!” - focused on creative dealmaking to optimize portfolio strategy in a fast-changing environment. Konstantina will share her perspective on the role of business development in building a resilient portfolio and in adapting to unexpected events. Please register here to attend our conference and meet and hear from Konstantina: ➡ https://lnkd.in/eN-fk_bv 📌𝗪𝗲 𝗵𝗮𝘃𝗲 𝗮𝗻 𝗘𝗮𝗿𝗹𝘆 𝗕𝗶𝗿𝗱 𝘀𝗽𝗲𝗰𝗶𝗮𝗹 𝘆𝗼𝘂 𝗰𝗮𝗻 𝗯𝗲𝗻𝗲𝗳𝗶𝘁 𝗳𝗿𝗼𝗺 - 𝗶𝗳 𝘆𝗼𝘂 𝗿𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗯𝗲𝗳𝗼𝗿𝗲 𝗙𝗲𝗯𝗿𝘂𝗮𝗿𝘆 𝟮𝟴𝘁𝗵, 𝟮𝟬𝟮𝟱 𝘁𝗵𝗲𝗻 𝘆𝗼𝘂 𝘄𝗶𝗹𝗹 𝗼𝗯𝘁𝗮𝗶𝗻 𝗮 𝟱𝟬% 𝗱𝗶𝘀𝗰𝗼𝘂𝗻𝘁 𝗼𝗻 𝘆𝗼𝘂𝗿 𝟮𝟬𝟮𝟱 𝗦𝘄𝗶𝘀𝘀 𝗛𝗟𝗚 𝗺𝗲𝗺𝗯𝗲𝗿𝘀𝗵𝗶𝗽 𝗳𝗲𝗲.📌 #swisshlg #biopharma #dealmaking #innovation #networking #SwissHLGconference

We would like to invite you to join us for our flagship annual conference which will once again be held at the historic Belle Epoque Grand Hotel Suisse Majestic in the beautiful scenic location of Montreux, Switzerland on 25th - 27th May 2025. 👉Register here ➡ https://lnkd.in/eN-fk_bv   Our conference is recognised for the consistently high quality of presenters and discussions. Fully 70% of respondents in our 2024 delegate survey rated the program, networking and location all as excellent! "𝘛𝘩𝘦 𝘦𝘷𝘦𝘯𝘵 𝘱𝘳𝘰𝘷𝘪𝘥𝘦𝘥 𝘷𝘢𝘭𝘶𝘢𝘣𝘭𝘦 𝘰𝘱𝘱𝘰𝘳𝘵𝘶𝘯𝘪𝘵𝘪𝘦𝘴 𝘵𝘰 𝘤𝘰𝘯𝘯𝘦𝘤𝘵 𝘸𝘪𝘵𝘩 𝘚𝘸𝘪𝘴𝘴 𝘉𝘋&𝘓 𝘱𝘳𝘰𝘧𝘦𝘴𝘴𝘪𝘰𝘯𝘢𝘭𝘴, 𝘱𝘩𝘢𝘳𝘮𝘢 𝘳𝘦𝘱𝘳𝘦𝘴𝘦𝘯𝘵𝘢𝘵𝘪𝘷𝘦𝘴, 𝘝𝘊𝘴, 𝘢𝘯𝘥 𝘣𝘪𝘰𝘵𝘦𝘤𝘩𝘴. 𝘛𝘩𝘦 𝘵𝘩𝘰𝘶𝘨𝘩𝘵-𝘱𝘳𝘰𝘷𝘰𝘬𝘪𝘯𝘨 𝘵𝘰𝘱𝘪𝘤𝘴 𝘢𝘯𝘥 𝘸𝘦𝘭𝘭-𝘱𝘳𝘦𝘴𝘦𝘯𝘵𝘦𝘥 𝘴𝘦𝘴𝘴𝘪𝘰𝘯𝘴 𝘵𝘳𝘶𝘭𝘺 𝘦𝘯𝘳𝘪𝘤𝘩𝘦𝘥 𝘮𝘺 𝘬𝘯𝘰𝘸𝘭𝘦𝘥𝘨𝘦.. 𝘉𝘦𝘺𝘰𝘯𝘥 𝘵𝘩𝘦 𝘪𝘯𝘧𝘰𝘳𝘮𝘢𝘵𝘪𝘷𝘦 𝘤𝘰𝘯𝘵𝘦𝘯𝘵, 𝘴𝘰𝘤𝘪𝘢𝘭 𝘪𝘯𝘵𝘦𝘳𝘢𝘤𝘵𝘪𝘰𝘯𝘴 𝘸𝘪𝘵𝘩 𝘱𝘦𝘦𝘳𝘴 𝘤𝘳𝘦𝘢𝘵𝘦𝘥 𝘢 𝘴𝘦𝘯𝘴𝘦 𝘰𝘧 𝘤𝘢𝘮𝘢𝘳𝘢𝘥𝘦𝘳𝘪𝘦, 𝘮𝘢𝘬𝘪𝘯𝘨 𝘵𝘩𝘦 𝘰𝘷𝘦𝘳𝘢𝘭𝘭 𝘦𝘹𝘱𝘦𝘳𝘪𝘦𝘯𝘤𝘦 𝘦𝘯𝘫𝘰𝘺𝘢𝘣𝘭𝘦... 𝘐’𝘮 𝘦𝘢𝘨𝘦𝘳 𝘵𝘰 𝘱𝘢𝘳𝘵𝘪𝘤𝘪𝘱𝘢𝘵𝘦 𝘪𝘯 𝘧𝘶𝘵𝘶𝘳𝘦 𝘦𝘷𝘦𝘯𝘵𝘴 𝘰𝘳𝘨𝘢𝘯𝘪𝘻𝘦𝘥 𝘣𝘺 𝘚𝘸𝘪𝘴𝘴 𝘏𝘓𝘎." Seyda Caskurlu, Head of New Business, Viatris 📌𝗪𝗲 𝗵𝗮𝘃𝗲 𝗮𝗻 𝗘𝗮𝗿𝗹𝘆 𝗕𝗶𝗿𝗱 𝘀𝗽𝗲𝗰𝗶𝗮𝗹 𝘆𝗼𝘂 𝗰𝗮𝗻 𝗯𝗲𝗻𝗲𝗳𝗶𝘁 𝗳𝗿𝗼𝗺 - 𝗶𝗳 𝘆𝗼𝘂 𝗿𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗯𝗲𝗳𝗼𝗿𝗲 𝗙𝗲𝗯𝗿𝘂𝗮𝗿𝘆 𝟮𝟴𝘁𝗵, 𝟮𝟬𝟮𝟱 𝘁𝗵𝗲𝗻 𝘆𝗼𝘂 𝘄𝗶𝗹𝗹 𝗼𝗯𝘁𝗮𝗶𝗻 𝗮 𝟱𝟬% 𝗱𝗶𝘀𝗰𝗼𝘂𝗻𝘁 𝗼𝗻 𝘆𝗼𝘂𝗿 𝟮𝟬𝟮𝟱 𝗦𝘄𝗶𝘀𝘀 𝗛𝗟𝗚 𝗺𝗲𝗺𝗯𝗲𝗿𝘀𝗵𝗶𝗽 𝗳𝗲𝗲.📌   The 2025 conference title is “Shaping your future..... Act now!” Creative dealmaking to optimize portfolio strategy in a fast- changing environment.   Dealmaking is a crucial tool in building a resilient, future-proofed portfolio for your company. Our conference will equip you with the perspectives, learnings and tools to achieve this goal. Our first session will look at key trends to consider in the biopharma environment, including therapeutic, technological, regulatory, payer and geopolitical developments. We then look at essential concepts to follow in building a portfolio and learn from successful practitioners. Finally, we will see how agile dealmaking an essential tool is when handling unexpected events.    We have an exciting lineup of speakers and panelists, with Keynote from David Veitch at Basilea Pharmaceutica and presentations from Melanie Senior, Sarah Thomae, Sian Tanner, Philippe Beaupere, Kelvin Stott, Karen Wagner, Frédéric L., Peter Louwagie, Marianne Spaene and Laura Jeanbart. We look forward to seeing you again in May! 👉Register here ➡ https://lnkd.in/eN-fk_bv #swisshlg #biopharma #dealmaking #innovation #networking #conference2025 #therapeutic #portfolio

The IPLS are pleased to extend our Super Early Bird discount until 28th February 2025. Register here: https://lnkd.in/e3bb6AR

Inscrivez-vous dès maintenant! / Register Now! www.lspartnering.ca

Our valuations team—Steve Waterman, Kyriakos Tzafestas PhD, and Thomas Hickman—have been tracking the dynamics of the early-stage biopharma VC market. In their latest snapshot, they highlight several intriguing contradictions in the data. While total amount of capital deployed in Series A rounds in 2024 exceeded 2019 levels, the number of new Series A investments dropped substantially. At the same time, reported valuations and the median amount of capital deployed in each investment appear to have risen dramatically. To put this in perspective: In 2024, 31% of Series A investments exceeded $50 million of invested capital, which is a sharp increase from just 4% in 2017. This data supports the observations of many commentators that VCs are investing larger amounts in more mature portfolios for their A rounds. However, it has been noted elsewhere that many otherwise successful companies have raised funds at valuations that have been repriced downwards or on similar terms to those achieved during the pandemic sugar rush. Down rounds are rarely publicized and there is clearly some degree of disclosure bias in today’s data.   Despite the green shoots of recovery, the environment remains challenging. 2023 and 2024 has been a story of layoffs as some companies seek to stretch their cash runway and hit critical data milestones that can secure new investment. For others, when data hasn’t worked out, it can be terminal, something we are seeing in the data around companies filing for bankruptcy.   Whilst there are some signs of an improving IPO market, the amount of capital raised at IPO in the last 4 quarters is still below that seen in 2019. IPO has only been a viable exit for just a handful of companies which when combined with notably low M&A levels during 2024, means that the exit environment continues to be muted. 2025 is going to be a very interesting year …   If you would like a no-obligation conversation with us, please contact our valuations team - Steve Waterman, Kyriakos Tzafestas PhD, Thomas Hickman, or drop us a line directly.   Previous Valuation Carousels https://lnkd.in/eDiz76bJ https://lnkd.in/eJ5jT7Wf   #Biotech #VentureCapital #Valuation